Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Pol Specenier. (2016) Ipilimumab in melanoma. Expert Review of Anticancer Therapy 16:8, pages 811-826.
Read now
Read now
Lorenzo Galluzzi, Alexander Eggermont & Guido Kroemer. (2016) Doubling the blockade for melanoma immunotherapy. OncoImmunology 5:1.
Read now
Read now
Articles from other publishers (52)
Paige H. Parrack, Stephen D. Zucker & Lei Zhao. (2023) Liver Pathology Related to Onco-Therapeutic Agents. Surgical Pathology Clinics 16:3, pages 499-518.
Crossref
Crossref
Islam Eljilany, Arish Noor, Mahati Paravathaneni, Ibrahim Yassine, Sandra J. Lee, Megan Othus, James Moon, John M. Kirkwood, Vernon K. Sondak, Antoni Ribas, Kenneth F. Grossmann & Ahmad A. Tarhini. (2023) Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review. Cancers 15:9, pages 2561.
Crossref
Crossref
Hassan Izzedine, Thibaud Chazal, Rimda Wanchoo & Kenar D Jhaveri. (2022) Immune checkpoint inhibitor–associated hypercalcaemia. Nephrology Dialysis Transplantation 37:9, pages 1598-1608.
Crossref
Crossref
Victoria Purcell, Beatrice Preti & Ricardo Fernandes. (2022)
Suspected immune checkpoint
inhibitor‐induced
pulmonary
sarcoid reaction
in metastatic renal cell carcinoma
. Clinical Case Reports 10:7.
Crossref
Crossref
Audrey Melin, Émilie Routier, Séverine Roy, Pauline Pradere, Jerome Le Pavec, Thibaut Pierre, Noémie Chanson, Jean-Yves Scoazec, Olivier Lambotte & Caroline Robert. (2022) Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma. Cancers 14:12, pages 2937.
Crossref
Crossref
Nupur N. Uppal, Biruh T. Workeneh, Helbert Rondon-Berrios & Kenar D. Jhaveri. (2022) Electrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy. Clinical Journal of the American Society of Nephrology 17:6, pages 922-933.
Crossref
Crossref
Matthew Scarlotta, Robin Avery, Ezra Baraban, Zahra Maleki & Yasser Ged. (2022) Case Report: New Onset Lymphadenopathy After Immune Checkpoint Inhibitor Therapy Presents a Clinicopathological and Radiological Challenge. Frontiers in Oncology 12.
Crossref
Crossref
Yuxin Lin, Wei Zhu, Bingchen Wu & Huiyin Lan. (2022) Case Report: Hepatic Sarcoid-Like Reaction Associated With Checkpoint Inhibition in a NSCLC Patient and a Literature Review. Frontiers in Oncology 12.
Crossref
Crossref
Babina Gosangi, Lacey McIntosh, Abhishek Keraliya, David Victor Kumar Irugu, Akshay Baheti, Ashish Khandelwal, Richard Thomas & Marta Braschi-Amirfarzan. (2022) Imaging features of toxicities associated with immune checkpoint inhibitors. European Journal of Radiology Open 9, pages 100434.
Crossref
Crossref
G.S. Shroff, C.D. Strange, M. Altan, B.W. Carter, J. Ahuja, M.C.B. Godoy, M.T. Truong & I. Vlahos. (2022) Post-immunotherapy imaging in lung cancer. Clinical Radiology 77:1, pages 44-57.
Crossref
Crossref
Divya Verma, Saadia A. Faiz, Vickie R. Shannon, Mehmet Altan & Ajay Sheshadri. 2022. Managing Immunotherapy Related Organ Toxicities. Managing Immunotherapy Related Organ Toxicities
275
299
.
Stratigoula Sakellariou, Dionysia N. Zouki, Dimitrios C. Ziogas, Despoina Pouloudi, Helen Gogas & Ioanna Delladetsima. (2021) Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review. BMC Gastroenterology 21:1.
Crossref
Crossref
Nicola M. Hughes & Heather A. Jacene. (2021) PET Imaging for Hematologic Malignancies. Radiologic Clinics of North America 59:5, pages 705-723.
Crossref
Crossref
J. Torres-Jiménez, J. Esteban-Villarrubia, P. García-Abellás, A. Cortés-Salgado, A. Soria-Rivas, P. Gajate-Borau, M. E. Olmedo-García, E. Corral-de la Fuente, Y. Lage-Alfranca, A. Gómez-Rueda, A. Benito-Berlinches, L. Gorospe-Sarasua & P. Garrido-López. (2021) Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital. Clinical and Translational Oncology 23:7, pages 1474-1480.
Crossref
Crossref
G.S. Shroff, S. Shroff, J. Ahuja, M.T. Truong & I. Vlahos. (2021) Imaging spectrum of adverse events of immune checkpoint inhibitors. Clinical Radiology 76:4, pages 262-272.
Crossref
Crossref
Semra Paydas. (2021) Sarcoid-like reaction in cases treated by checkpoint inhibitors. Medical Oncology 38:3.
Crossref
Crossref
Mark A Anderson, Vikram Kurra, William Bradley, Aoife Kilcoyne, Amirkasra Mojtahed & Susanna I Lee. (2021) Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography. The British Journal of Radiology 94:1118, pages 20200663.
Crossref
Crossref
Stephen D. H. Malnick, Ali Abdullah & Manuela G. Neuman. (2021) Checkpoint Inhibitors and Hepatotoxicity. Biomedicines 9:2, pages 101.
Crossref
Crossref
De Keukeleire Stijn, Schwarze Julia, Awada Gil, Everaert Hendrik, Van Binst Anne Marie, Cras Louise, Neyns Bart & Aspeslagh Sandrine. (2020) An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma. Melanoma Research Publish Ahead of Print.
Crossref
Crossref
Thoetchai (Bee) Peeraphatdit, Jennifer Wang, Matthew A. Odenwald, Shaomin Hu, John Hart & Michael R. Charlton. (2020) Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. Hepatology 72:1, pages 315-329.
Crossref
Crossref
Enrico Matteo Garanzini, Davide Scaramuzza, Gaia Spadarella, Lorenza Di Guardo & Alfonso Marchianò. (2020) Sarcoidosis-like disease mimicking metastases during adjuvant ipilimumab therapy in advanced melanoma patient: CT scan and MRI help in managing difficult clinical decision. BJR|case reports 6:2, pages 20190065.
Crossref
Crossref
Cindy Ung & Evangelos Gragoudas. (2020) Checkpoint inhibitor-induced sarcoid choroidal granulomas. American Journal of Ophthalmology Case Reports 18, pages 100652.
Crossref
Crossref
Vanina Vani, Daniele Regge, Giovanni Cappello, Michela Gabelloni & Emanuele Neri. (2020) Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy. Diagnostics 10:4, pages 216.
Crossref
Crossref
Yoh Zen, Yen‐Ying Chen, Yung‐Ming Jeng, Hung‐Wen Tsai & Matthew M Yeh. (2019) Immune‐related adverse reactions in the hepatobiliary system: second‐generation check‐point inhibitors highlight diverse histological changes. Histopathology 76:3, pages 470-480.
Crossref
Crossref
Nirosshan Thiruchelvam, Venkat Rajasurya, Sivagowri Tharmendira, Heather Torbic, Madeline Waldron, James K. Stoller & Daniel A. Culver. (2020) Immune-related Pulmonary Toxicity From Cancer Immunotherapy: A Systematic Approach. Clinical Pulmonary Medicine 27:6, pages 183-192.
Crossref
Crossref
Carrie Ye, Shahin Jamal, Marie Hudson, Aurore Fifi-Mah & Janet Roberts. (2019) Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments. Current Treatment Options in Rheumatology 5:4, pages 272-289.
Crossref
Crossref
Christine M. Cornejo, Paul Haun, Joseph EnglishIIIIII & Misha Rosenbach. (2019) Immune checkpoint inhibitors and the development of granulomatous reactions. Journal of the American Academy of Dermatology 81:5, pages 1165-1175.
Crossref
Crossref
Pooja H. Rambhia, Barbara Reichert, Jeffrey F. Scott, Ashley N. Feneran, Jordan A. Kazakov, Kord Honda, Henry Koon & Meg R. Gerstenblith. (2019) Immune checkpoint inhibitor-induced sarcoidosis-like granulomas. International Journal of Clinical Oncology 24:10, pages 1171-1181.
Crossref
Crossref
Hei-Cheul Jeung, Se Eung OhJee Hung Kim. (2019) Immune-related Adverse Events: Overview and Management Strategies for the Use of Immune Checkpoint Inhibitors. Journal of Rheumatic Diseases 26:4, pages 221.
Crossref
Crossref
Esmée P. Hoefsmit, Elisa A. Rozeman, John B.A.G. Haanen & Christian U. Blank. (2019) Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. ESMO Open 4:4, pages e000472.
Crossref
Crossref
J. Cervantes, A. Rosen, L. Dehesa, G. Dickinson & J. Alonso-Llamazares. (2019) Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings. Actas Dermo-Sifiliográficas (English Edition) 110:1, pages 43-49.
Crossref
Crossref
J. Cervantes, A. Rosen, L. Dehesa, G. Dickinson & J. Alonso-Llamazares. (2019) Reacción granulomatosa en paciente con melanoma metastásico tratado con ipilimumab: primer caso descrito presentando clínica cutánea únicamente. Actas Dermo-Sifiliográficas 110:1, pages 43-49.
Crossref
Crossref
Michael T. Tetzlaff, Kelly C. Nelson, Adi Diab, Gregg A. Staerkel, Priyadharsini Nagarajan, Carlos A. Torres-Cabala, Beth A. Chasen, Jennifer A. Wargo, Victor G. Prieto, Rodabe N. Amaria & Jonathan L. Curry. (2018) Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. Journal for ImmunoTherapy of Cancer 6:1.
Crossref
Crossref
Michael A Mitchell, Kevin Hogan & Kayvan Amjadi. (2018) Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinoma. Immunotherapy 10:14, pages 1189-1192.
Crossref
Crossref
Amit Chopra, Amit Nautiyal, Alexander Kalkanis & Marc A. Judson. (2018) Drug-Induced Sarcoidosis-Like Reactions. Chest 154:3, pages 664-677.
Crossref
Crossref
David J. Palmieri & Matteo S. Carlino. (2018) Immune Checkpoint Inhibitor Toxicity. Current Oncology Reports 20:9.
Crossref
Crossref
Ioannis Gkiozos, Alexandra Kopitopoulou, Alexandros Kalkanis, Ioannis N. Vamvakaris, Marc A. Judson & Konstantinos N. Syrigos. (2018) Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors. Journal of Thoracic Oncology 13:8, pages 1076-1082.
Crossref
Crossref
Florentia Dimitriou, Anna L. Frauchiger, Mirjana Urosevic-Maiwald, Mirjam C. Naegeli, Simone M. Goldinger, Marjam Barysch, Daniel Franzen, Jivko Kamarachev, Ralph Braun, Reinhard Dummer & Joanna Mangana. (2018) Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Research 28:3, pages 230-236.
Crossref
Crossref
Eleonora De Martin, Jean-Marie Michot, Barbara Papouin, Stéphane Champiat, Christine Mateus, Olivier Lambotte, Bruno Roche, Teresa Maria Antonini, Audrey Coilly, Salim Laghouati, Caroline Robert, Aurélien Marabelle, Catherine Guettier & Didier Samuel. (2018) Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. Journal of Hepatology 68:6, pages 1181-1190.
Crossref
Crossref
Hana Studentova, Hana Kalabova, Pavel Koranda, Karin Chytilova, Ladislava Kucerova, Bohuslav Melichar & David Vrana. (2018) Immunotherapy in mucosal melanoma: a case report and review of the literature. Oncotarget 9:25, pages 17971-17977.
Crossref
Crossref
N. Yatim, C. Mateus & P. Charles. (2018) Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission. La Revue de Médecine Interne 39:2, pages 130-133.
Crossref
Crossref
S. Cousin, J. Seneschal & A. Italiano. (2018) Toxicity profiles of immunotherapy. Pharmacology & Therapeutics 181, pages 91-100.
Crossref
Crossref
Sarah Sammons, Megan McNamara, April K. S. Salama & Jeffrey Crawford. 2018. Side Effects of Medical Cancer Therapy. Side Effects of Medical Cancer Therapy
315
353
.
I. Puzanov, A. Diab, K. Abdallah, C. O. Bingham, C. Brogdon, R. Dadu, L. Hamad, S. Kim, M. E. Lacouture, N. R. LeBoeuf, D. Lenihan, C. Onofrei, V. Shannon, R. Sharma, A. W. Silk, D. Skondra, M. E. Suarez-Almazor, Y. Wang, K. Wiley, H. L. Kaufman & M. S. Ernstoff. (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. Journal for ImmunoTherapy of Cancer 5:1.
Crossref
Crossref
J. Hoffend, C. Sachpekidis & A. Dimitrakopoulou-Strauss. (2017) Nuklearmedizinische ResponsebeurteilungResponse evaluation in nuclear medicine. Der Radiologe 57:10, pages 834-839.
Crossref
Crossref
Joshua E. Reuss, Paul R. Kunk, Anne M. Stowman, Alejandro A. Gru, Craig L. Slingluff & Elizabeth M. Gaughan. (2016) Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature. Journal for ImmunoTherapy of Cancer 4:1.
Crossref
Crossref
Hampig R. Kourie, Gil Awada & Ahmad H. Awada. (2016) Rare side-effects of checkpoint inhibitors. Current Opinion in Oncology 28:4, pages 295-305.
Crossref
Crossref
Kathleen C. Suozzi, Maximilian Stahl, Christine J. Ko, Anne Chiang, Scott N. Gettinger, Mark D. Siegel & Christopher G. Bunick. (2016) Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Reports 2:3, pages 264-268.
Crossref
Crossref
François-Xavier Danlos, Cécile Pagès, Barouyr Baroudjian, Laetitia Vercellino, Maxime Battistella, Maurice Mimoun, Majdi Jebali, Martine Bagot, Abdellatif Tazi & Céleste Lebbé. (2016) Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma. Chest 149:5, pages e133-e136.
Crossref
Crossref
Sofie WilgenhofJurgen CorthalsCarlo HeirmanNicolas van BarenSophie LucasPia KvistborgKris ThielemansBart Neyns. (2016) Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. Journal of Clinical Oncology 34:12, pages 1330-1338.
Crossref
Crossref
Lavinia Spain, Stefan Diem & James Larkin. (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treatment Reviews 44, pages 51-60.
Crossref
Crossref
Shannon K. Quirk, Anna K. Shure & Devendra K. Agrawal. (2015) Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma. Translational Research 166:5, pages 412-424.
Crossref
Crossref